Jyong Biotech Ltd. (NASDAQ:MENS) Short Interest Down 19.5% in February

Jyong Biotech Ltd. (NASDAQ:MENS) was the target of a significant decrease in short interest during the month of February. As of February 27th, there was short interest totaling 373,692 shares, a decrease of 19.5% from the February 12th total of 464,337 shares. Based on an average trading volume of 422,857 shares, the days-to-cover ratio is presently 0.9 days. Approximately 0.5% of the shares of the stock are sold short. Approximately 0.5% of the shares of the stock are sold short. Based on an average trading volume of 422,857 shares, the days-to-cover ratio is presently 0.9 days.

Wall Street Analysts Forecast Growth

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of Jyong Biotech in a research note on Thursday, January 22nd. One research analyst has rated the stock with a Sell rating, According to MarketBeat, the company has a consensus rating of “Sell”.

Institutional Trading of Jyong Biotech

Several institutional investors and hedge funds have recently added to or reduced their stakes in the stock. BNP Paribas Financial Markets purchased a new position in shares of Jyong Biotech in the 3rd quarter valued at approximately $67,000. Geode Capital Management LLC raised its stake in shares of Jyong Biotech by 19.6% during the fourth quarter. Geode Capital Management LLC now owns 64,382 shares of the company’s stock worth $254,000 after purchasing an additional 10,538 shares during the last quarter. China Universal Asset Management Co. Ltd. acquired a new stake in shares of Jyong Biotech during the fourth quarter worth $49,000. Millennium Management LLC purchased a new position in Jyong Biotech in the 3rd quarter valued at $512,000. Finally, Man Group plc acquired a new position in Jyong Biotech in the 4th quarter valued at $56,000.

Jyong Biotech Stock Down 9.1%

MENS stock traded down $0.18 on Tuesday, hitting $1.80. The company’s stock had a trading volume of 376,493 shares, compared to its average volume of 350,879. The firm has a 50 day moving average of $2.48 and a two-hundred day moving average of $25.82. Jyong Biotech has a 1 year low of $1.43 and a 1 year high of $67.00.

Jyong Biotech (NASDAQ:MENS) last issued its quarterly earnings data on Friday, January 9th. The company reported ($0.01) earnings per share (EPS) for the quarter.

About Jyong Biotech

OUR MISSION We endeavor to develop and supply first-class innovative drugs to meet our customers’ health needs. We seek to be a valuable business organization that is held in high esteem by the public. We are a science-driven biotechnology company based in Taiwan and are committed to developing and commercializing innovative and differentiated new drugs (plant-derived) mainly specializing in the treatment of urinary system diseases, with an initial focus on the markets of the U.S., the EU, and Asia.